Recent studies have revealed that mutated KRAS expression is associated with reduced anticancer activity of gemcitabine and paclitaxel, the drugs currently used in the clinical treatment of pancreatic cancer, and new therapeutic strategies of targeting KRAS should inhibit tumor cell growth and combat drug resistance (Kimmelman, 2015; Grasso et al., 2017). Here, KRAS is linked to familial pancreatic carcinoma.